Phosphorothioate oligodeoxynucleotides: Large-scale synthesis and analysis, impurity characterization, and the effects of phosphorus stereochemistry

CIBA Foundation Symposia

Volumn , Issue 209, 1997, Pages 19-37

  Fearon, Karen L ^a   Hirschbein, Bernard L ^a   Chiu, Choi Ying ^a   Quijano, Maria R ^a   Zon, Gerald ^a  

^a ILLUMINA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOTIDE; OLIGODEOXYRIBONUCLEOTIDE; PHOSPHORUS;

CHEMISTRY; CONFORMATION; HUMAN; REVIEW; SYNTHESIS;

HUMANS; MOLECULAR CONFORMATION; OLIGODEOXYRIBONUCLEOTIDES; PHOSPHORUS; THIONUCLEOTIDES;

EID: 0031299443     PISSN: 03005208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. BioWorld Today 1996 Isis, Ciba finalize collaboration, take first compound into clinic. 7:1-2
2. Bishop MR, Iversen PL, Bayever E et al 1996 Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol 14:1320-1326
3. Chen J-K, Schultz RG, Lloyd DH, Gryaznov SM 1995 Synthesis of oligodeoxyribonucleotide N3′→P5′ phosphoramidates. Nucleic Acids Res 23:2661-2668
4. Fearon KL, Stults JT, Bergot BJ, Christenesen LM, Raible AM 1995 Investigation of the 'n-1' impurity in phosphorothioate oligodeoxynucleotides synthesized by the solid-phase β-cyanoethyl phosphoramidite method using stepwise sulfurization. Nucleic Acids Res 23:2754-2761
5. 6-protecting group for deoxyadenosine. Nucleic Acids Res 11:8031-8036
6. Galbraith WM, Hobson WC, Giclas RC, Schechter PJ, Agrawal S 1994 Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev 4:201-206
7. Gewirtz AW, Luger S, Sokol D et al 1996 Treating human myelogenous leukemia with c-myb antisense oligodeoxynucleotides: two years clinical experience. J Invest Med 44:279A
8. Giles RV, Spiller DG, Tidd DM 1995 Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. Antisense Res Dev 5:23-31
9. Groebke K, Leumann C 1990 A method for preparing oligodeoxynucleotides containing an apurinic site. Helv Chim Acta 73:608-617
10. Gryaznov SM, Lloyd DH, Chen J-K et al 1995 Oligonucleotide N3′→P5′ phosphoramidates. Proc Natl Acad Sci USA 92:5798-5802
11. Gryaznov S, Skorski T, Cucco C et al 1996 Oligonucleotide N3′→P5′ phosphoramidates as antisense agents. Nucleic Acids Res 24:1508-1514
12. Horn T, Urdea MS 1988 Solid supported hydrolysis of apurinic sites in synthetic oligonucleotides for rapid and efficient purification on reverse-phase cartridges. Nucleic Acids Res 16:11559-11571
13. Iyer RP, Phillips LR, Egan W, Regan JB, Beaucage SL 1990 The automated synthesis of sulfur-containing oligodeoxyribonucleotides using 3-H-1,2-benzodithiol-3-one 1,1-dioxide as a sulfur-transfer reagent. J Org Chem 55:4693-4699
14. Kambhampati RVB, Chiu Y-Y, Chen CW, Blumenstein JJ 1993 Regulatory concerns for the chemistry, manufacturing, and controls of oligonucleotide therapeutics for use in clinical studies. Antisense Res Dev 3:405-410
15. Koziolkiewicz M, Krakowiak A, Kwinkowski M, Boczkowska M, Stec WJ 1995 Stereodifferentiation - the effect of P chirality of oligo(nucleoside phosphorothioates) on the activity of bacterial RNase H. Nucleic Acids Res 23:5000-5005
16. McCollum C, Andrus A 1991 An optimized polystyrene support for rapid, efficient oligonucleotide synthesis. Tetrahedron Lett 32:4069-4072
17. McCurdy SN, Nelson JS, Hirschbein BL, Fearon KL 1997 An improved method for the synthesis of N3′→P5′ phosphoramidate oligonucleotides. Tetrahedron Lett 38:207-210
18. Ratajczak MZ, Kant J A, Luger SM et al 1992 In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 89:11823-11827
19. Shi Y, Fard A, Galeo A et al 1994 Transcatheter delivery of c-myc antisense oligomers reduced neointimal formation in a porcine model of coronary artery balloon injury. Circulation 90:944-951
20. Skorski T, Perrotti D, Nieborowska-Skorska M, Gryaznov S, Calabretta B 1997 Antileukemic effect of c-myc N3′→P5′ phosphoramidate antisense oligonucleotide in vivo. Proc Natl Acad Sci USA 94:3966-3971
21. Stec WJ, Uznanski B, Wilk A, Hirschbein BL, Fearon KL, Bergot BJ 1993 Bis(O,O-diisopropoxy phosphinothioyl) disulfide: a highly efficient sulfurizing reagent for cost-effective synthesis of oligo(nucleoside phosphorothioate)s. Tetrahedron Lett 34:5317-5320
22. Stec WJ, Grajkowski A, Kobylanska A et al 1995 Diastereomers of nucleoside 3′-O-(2-thio-1,3,2-oxathia(selena)phospholanes): building blocks for stereocontrolled synthesis of oligo(nucleoside phosphorothioate)s. J Am Chem Soc 117:12019-12029
23. P) oligonucleotide phosphorothioate and its properties. Nucleosides Nucleotides 14:985-990
24. Temsamani J, Kubert M, Agrawal S 1995 Sequence identity of the n-1 product of a synthetic oligonucleotide. Nucleic Acids Res 23:1841-1844
25. Uhlmann E, Peyman A 1990 Antisense oligonucleotides: a new therapeutic principle. Chem Rev 90:543-584
26. Zon G 1990 Purification of synthetic oligodeoxyribonucleotides. In: Hancock WS (ed) High performance liquid chromatography in biotechnology. Wiley, New York, p 301-397